Pharmacologic class:

Topical corticosteroid (low potency)

Continue Reading

Active ingredient:

Desonide 0.05%; topical foam.


Mild-to-moderate atopic dermatitis in patients older than 3 months of age.


Desonide, like other topical corticosteroids, has anti-inflammatory, antipruritic, and vasoconstrictive actions. Verdeso is a petroleum-based emulsion formulation of desonide that is dispensed as an aerosol foam. Topical corticosteroids can be absorbed through the skin, and the extent of absorption depends on the formulation, the integrity of the skin, and the presence or absence of occlusive dressings. After being absorbed into the skin, topically applied corticosteroids can have systemic effects, such as adrenal suppression. They are metabolized mostly by the liver and excreted by the kidneys.

It has been postulated that corticosteroids act by inducing phospholipase A2 inhibitory proteins (lipocortins). These proteins control the biosynthesis of mediators of the inflammatory response such as prostaglandins and leukotrienes by inhibiting the release of their precursor, arachidonic acid, from membrane phospholipids.

Clinical trials:

The efficacy of this product was evaluated in a double-blind, randomized clinical trial involving 581 patients with mild-to-moderate atopic dermatitis. The patients were 3 months to 17 years of age. Either Verdeso foam or vehicle was applied twice daily for four weeks. In the group using Verdeso foam, 39% of the patients experienced “success” compared with 9% for vehicle. Success was defined as the proportion of patients who had the following: an Investigator’s Static Global Assessment (ISGA) score of “clear or almost clear,” a minimum improvement in the five-point ISGA score of two grades from baseline to week 4, and a score of absent or minimal for both erythema and induration/papulation at week 4.

In another study, three of 75 pediatric patients (aged 6 months to 17 years) with mild-to-moderate atopic dermatitis covering at least 25% of body surface area who applied Verdeso twice daily experienced reversible adrenal suppression after four weeks of therapy.

All subjects’ cortisol levels returned to normal four weeks post-treatment. Adults and children: 3 months: apply thin layer to affected area twice daily; max 4 weeks’ therapy. Do not apply directly to face (use hands to apply). Occlude only if necessary.


Exclude viral disease (e.g., chickenpox, measles).


Treat infections if present; discontinue if infection persists or worsens. Systemic absorption may be increased by broken or inflamed skin, prolonged use, application to large surface area, or use of occlusive dressings. Discontinue or reduce dose if evidence of HPA axis suppression, Cushing’s syndrome, hyperglycemia, glucosuria, or irritation occurs. Use lowest effective dose (especially in children). Re-evaluate periodically. Avoid eyes, mucous membranes. Product is flammable. Pregnancy (Cat. C). Nursing mothers.

Adverse reactions:

Local effects, upper respiratory tract infections, headache, elevated BP.

How supplied:

Foam — 50 g, 100 g.

For more information, call 888.500.DERM, or visit